Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 48.34 |
---|---|
High | 50.69 |
Low | 47.57 |
Bid | 47.90 |
Offer | 52.00 |
Previous close | 46.44 |
Average volume | 337.65k |
---|---|
Shares outstanding | 64.40m |
Free float | 63.58m |
P/E (TTM) | -- |
Market cap | 2.99bn USD |
EPS (TTM) | -2.41 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
- Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
- Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
- Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
- Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
- Kymera Therapeutics to Participate in Upcoming June Investor Conferences
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
- Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
More ▼